National Lung Screening Trial

From WikiMD's Medical Encyclopedia

(Redirected from NLST)

National Lung Screening Trial (NLST) was a large-scale, randomized, national trial involving tens of thousands of participants. The trial was designed to determine whether screening with low-dose helical computed tomography (CT) could reduce mortality from lung cancer compared to standard chest X-ray.

Overview[edit]

The National Cancer Institute (NCI) sponsored the NLST, which was launched in 2002 and involved more than 53,000 current or former heavy smokers aged 55 to 74. Participants were randomly assigned to receive three annual screenings with either low-dose helical CT or standard chest X-ray.

Results[edit]

The results of the NLST, published in 2011, showed that participants who received low-dose helical CT scans had a 20% lower risk of dying from lung cancer than participants who received standard chest X-rays. These findings provided the first clear evidence that CT screening could reduce the risk of dying from this disease.

Impact[edit]

The results of the NLST have had a significant impact on public health policy and clinical practice. In 2013, the U.S. Preventive Services Task Force (USPSTF) recommended annual screening for lung cancer with low-dose CT in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years.

See also[edit]

References[edit]

<references />

This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia


Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.